Manufactures active pharmaceutical ingredients (APIs), which account for 88% of FY26 revenue, with a smaller formulations business that reached break-even. Operations are anchored at a manufacturing facility in Tanuku, Andhra Pradesh, which is inspected by overseas regulators including the USFDA and Australia's TGA. The company sells APIs such as Metformin HCl and supplies them to generic drug partners in the US, with drug master files (DMFs) filed in the US and South Korea. New APIs are being added to the portfolio, including an anaesthetic API launched in Q4 FY26, with a stated plan to add four new molecules a year from FY27. Costs are dominated by raw materials at 42% of revenue, followed by employees at 18.4% and other operating expenses at 22.7%. A new 82%-owned Indian subsidiary, Wanbury Skin Health Limited, has been incorporated in the pharma space. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Active Pharmaceutical Ingredients (APIs) (88%), Formulations. Asset-light API manufacturer serving global generic pharma, with an early-stage formulations and skin-health extension
| ₹ crore · consolidated | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 393 | 511 | 500 | 576 | 600 |
| EBITDA (ex other income) | 18 | 112 | 23 | 96 | 76 |
| margin % | 4.6 | 21.8 | 4.5 | 16.6 | 12.7 |
| Owners' profit | (13) | 0 | (10) | 0 | 31 |
| EPS, as reported (₹) | (5.04) | 26.88 | (6.18) | 26.39 | 9.32 |
| ROE % · ROCE % | 8.1 · (16.1) | (347.9) · (1408.4) | 31.7 · (67.3) | 200.3 · 66.1 | 51.5 · 27.8 |
| Debt / equity (x) | (0.57) | (2.86) | (1.95) | 3.94 | 2.92 |
| Cash from operations | 17 | 38 | 20 | 4 | 26 |
| Capex | 0 | 0 | 0 | (17) | (49) |
| ₹ crore | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 144 | 145 | 139 | 131 | 161 | 133 | 172 | 163 |
| Profit before tax | 7 | 10 | 34 | 1 | 8 | 1 | 19 | 14 |
| Net profit | 7 | 10 | 34 | 1 | 8 | 1 | 20 | 13 |
| EPS (₹) | 2.25 | 3.13 | 12.75 | 0.32 | 2.44 | 0.76 | 6.18 | 4.12 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Wanbury 38th AGM notice published in newspapers | compliance | minimal | — | — |
| 31 Aug 2026 · Record date for meeting set as 18 September 2026 | board shareholder meetings | low | — | — |
| 31 Aug 2026 · Wanbury 38th AGM on Sep 24, 2026; director re-appointment resolutions | board shareholder meetings | low | — | — |
| 28 Aug 2026 · Wanbury submits newspaper clippings for 38th AGM notice | compliance | minimal | — | — |
| 13 Aug 2026 · Wanbury gets EDQM nod for Rivaroxaban API, USFDA DMF clearances | business updates | high | — | — |
| 11 Aug 2026 · Wanbury Q1 FY27 results: PAT falls 76% YoY on input cost spike | compliance | low | — | — |
| 11 Aug 2026 · Wanbury board clears Q1 FY27 results, ESOP allotment and director re-appointment | capital market events | low | — | — |
| 11 Aug 2026 · Wanbury Q1 results, ESOP allotment, re-appointment of Whole-time Director | management changes | high | — | — |
| 11 Aug 2026 · Wanbury Q1 FY27 Results: PAT Falls 76% YoY, ESOP Allotment, Director Re-appointment | results | high | — | — |
| 3 Aug 2026 · Wanbury board to consider Q1 FY27 results on Aug 11, 2026 | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 17.7 | 28.9 | 49 of 169 | 71% |
| P/B | 14.1 | 3.3 | 151 of 163 | 7% |
| ROCE | 12.3 | 10.8 | 81 of 183 | 56% |
| ROE | 51.5 | 10.4 | 5 of 171 | 98% |
| Debt / Equity | 2.9 | 0.1 | 169 of 171 | 1% |
| EBITDA margin | 15.2 | 17.5 | 91 of 165 | 45% |
| Revenue growth | 24.5 | 16.3 | 61 of 161 | 63% |
| Profit growth | 1200.4 | 30.9 | 6 of 158 | 97% |
| Market cap | 835 | 839 | 92 of 182 | 50% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
